These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 15991041

  • 21. High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation.
    Sikma MA, Hunault CC, Van Maarseveen EM, Huitema ADR, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW.
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):123-134. PubMed ID: 31745812
    [Abstract] [Full Text] [Related]

  • 22. Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach.
    Nanga TM, Doan TTP, Marquet P, Musuamba FT.
    Br J Clin Pharmacol; 2019 Dec; 85(12):2793-2823. PubMed ID: 31471970
    [Abstract] [Full Text] [Related]

  • 23. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.
    Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC.
    Bone Marrow Transplant; 2001 Oct; 28(8):753-8. PubMed ID: 11781626
    [Abstract] [Full Text] [Related]

  • 24. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
    Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A.
    Clin Pharmacokinet; 2009 Oct; 48(12):805-16. PubMed ID: 19902988
    [Abstract] [Full Text] [Related]

  • 25. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.
    Kassir N, Labbé L, Delaloye JR, Mouksassi MS, Lapeyraque AL, Alvarez F, Lallier M, Beaunoyer M, Théorêt Y, Litalien C.
    Br J Clin Pharmacol; 2014 Jun; 77(6):1051-63. PubMed ID: 24977292
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE.
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies.
    Saint-Marcoux F, Knoop C, Debord J, Thiry P, Rousseau A, Estenne M, Marquet P.
    Clin Pharmacokinet; 2005 Feb; 44(12):1317-28. PubMed ID: 16372829
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients.
    Grover A, Frassetto LA, Benet LZ, Chakkera HA.
    Drug Metab Dispos; 2011 Nov; 39(11):2017-9. PubMed ID: 21849516
    [Abstract] [Full Text] [Related]

  • 34. Total plasma protein effect on tacrolimus elimination in kidney transplant patients--population pharmacokinetic approach.
    Golubović B, Vučićević K, Radivojević D, Kovačević SV, Prostran M, Miljković B.
    Eur J Pharm Sci; 2014 Feb 14; 52():34-40. PubMed ID: 24184751
    [Abstract] [Full Text] [Related]

  • 35. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.
    Antignac M, Barrou B, Farinotti R, Lechat P, Urien S.
    Br J Clin Pharmacol; 2007 Dec 14; 64(6):750-7. PubMed ID: 17425625
    [Abstract] [Full Text] [Related]

  • 36. Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation.
    Musuamba FT, Guy-Viterbo V, Reding R, Verbeeck RK, Wallemacq P.
    Ther Drug Monit; 2014 Feb 14; 36(1):54-61. PubMed ID: 24081207
    [Abstract] [Full Text] [Related]

  • 37. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data.
    Ben Fredj N, Woillard JB, Debord J, Chaabane A, Boughattas N, Marquet P, Saint-Marcoux F, Aouam K.
    Exp Clin Transplant; 2016 Aug 14; 14(4):394-400. PubMed ID: 27506258
    [Abstract] [Full Text] [Related]

  • 38. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation.
    Fukudo M, Yano I, Fukatsu S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K.
    Clin Pharmacokinet; 2003 Aug 14; 42(13):1161-78. PubMed ID: 14531726
    [Abstract] [Full Text] [Related]

  • 39. Development and validation of individualized tacrolimus dosing software for Chinese pediatric liver transplantation patients: a population pharmacokinetic approach.
    Yang S, Wei J, Pan X, Li Z, Zhang X, Li Z, Dong X, Hua Z, Li X.
    Eur J Clin Pharmacol; 2024 Sep 14; 80(9):1409-1420. PubMed ID: 38904798
    [Abstract] [Full Text] [Related]

  • 40. Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients.
    Andreu F, Colom H, Grinyó JM, Torras J, Cruzado JM, Lloberas N.
    Ther Drug Monit; 2015 Apr 14; 37(2):246-55. PubMed ID: 25254416
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.